SG Americas Securities LLC Has $150,000 Position in Neumora Therapeutics, Inc. (NASDAQ:NMRA)

SG Americas Securities LLC trimmed its holdings in Neumora Therapeutics, Inc. (NASDAQ:NMRA) by 34.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 14,119 shares of the company’s stock after selling 7,462 shares during the quarter. SG Americas Securities LLC’s holdings in Neumora Therapeutics were worth $150,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently made changes to their positions in NMRA. JPMorgan Chase & Co. increased its stake in Neumora Therapeutics by 2.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 64,421 shares of the company’s stock valued at $851,000 after purchasing an additional 1,629 shares in the last quarter. Handelsbanken Fonder AB raised its position in shares of Neumora Therapeutics by 35.0% in the third quarter. Handelsbanken Fonder AB now owns 26,600 shares of the company’s stock valued at $351,000 after purchasing an additional 6,900 shares during the period. Intech Investment Management LLC purchased a new position in Neumora Therapeutics during the 3rd quarter valued at about $175,000. Ballentine Partners LLC purchased a new stake in shares of Neumora Therapeutics in the third quarter worth $178,000. Finally, Point72 Asset Management L.P. bought a new position in shares of Neumora Therapeutics in the 3rd quarter worth $1,097,000. 47.65% of the stock is owned by institutional investors and hedge funds.

Neumora Therapeutics Price Performance

NASDAQ NMRA opened at $1.78 on Tuesday. The business has a 50 day simple moving average of $5.98 and a two-hundred day simple moving average of $10.04. Neumora Therapeutics, Inc. has a 1-year low of $1.71 and a 1-year high of $21.00. The stock has a market capitalization of $287.58 million, a PE ratio of -0.95 and a beta of 2.50.

Neumora Therapeutics (NASDAQ:NMRA) last released its earnings results on Tuesday, November 12th. The company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.06). During the same quarter in the previous year, the company earned ($1.14) earnings per share. On average, analysts anticipate that Neumora Therapeutics, Inc. will post -1.61 EPS for the current fiscal year.

Analysts Set New Price Targets

NMRA has been the subject of several analyst reports. HC Wainwright restated a “buy” rating and set a $30.00 target price on shares of Neumora Therapeutics in a report on Friday, January 3rd. Bank of America cut their price objective on shares of Neumora Therapeutics from $22.00 to $7.00 and set a “buy” rating on the stock in a report on Monday, January 6th. JPMorgan Chase & Co. downgraded shares of Neumora Therapeutics from an “overweight” rating to a “neutral” rating and cut their price objective for the company from $18.00 to $15.00 in a research report on Tuesday, November 5th. Royal Bank of Canada downgraded shares of Neumora Therapeutics from an “outperform” rating to a “sector perform” rating and dropped their price target for the company from $29.00 to $4.00 in a report on Thursday, January 2nd. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $23.00 price target on shares of Neumora Therapeutics in a research report on Thursday, January 2nd. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $16.50.

Neumora Therapeutics Profile

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.